Mylan wants to capture chronic Hep B market

The drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection here, Mylan added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news